Albumin therapy and intrauterine growth retardation in gestosis.
Intravenous administrations of albumin, 8-16 g for 5-46 days, to the total doses of 56-736 g (averaged 198 g) were given for 10 patients suffered from both EPH gestosis and hypoalbuminemia averaged 2.4 g/dl. Plasma albumin level, total proteins and A/G ratio were elevated from 2.4 to 3.3 g/dl, from 4.9 to 5.8 g/dl, and from 0.97 to 1.28, respectively in average, following the albumin therapies. Slight decreases in hematocrit, urinary protein, SGOT and SGPT were observed, while BUN increased slightly. Pregnancies were maintained until 36.7 weeks in average. Fourteen newborn infants were delivered in good conditions, mean birth weight being 2,475 g. Four infants (28.6%) were SFDs, while ten (71.4%) were AFDs. Intravenous albumin therapies appear to be safe and effective for those who have both EPH gestosis and hypoalbuminemia.
D000328:Adult; D000418:Albumins / Q000008:administration & dosage* / Q000627:therapeutic use; D001810:Blood Volume; D005260:Female; D005317:Fetal Growth Retardation / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007231:Infant, Newborn; D007263:Infusions, Parenteral; D011225:Pre-Eclampsia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy* / Q000503:physiopathology; D011255:Pregnancy Maintenance; D012709:Serum Albumin / Q000032:analysis
D000418:Albumins; D012709:Serum Albumin